Obesity

Illustration of the concept of layoff and downsizing of staff

Biomea cuts staff, drops leukemia asset in metabolic shift

Biomea is homing in on lead asset icovamenib, a menin inhibitor designed to address the underlying cause of diabetes, and a preclinical GLP-1 agonist.

Darren Incorvaia May 5, 2025 6:59pm

FDA lifts hold on Amgen's phase 1 obesity study

May 2, 2025 10:10am

Relmada reconsiders plans to test psilocybin for obesity

Mar 28, 2025 10:00am

Novo pens $2B deal for triple agonist weight loss drug

Mar 24, 2025 9:50am

'Not a cost-cutting exercise': Novo Nordisk reshapes R&D setup

Mar 20, 2025 10:15am

Opko, Entera share cost of 1st oral GLP-1/glucagon agonist study

Mar 17, 2025 10:10am